AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
AngioDynamics, Inc. (ANGIO) filed this Current Report on Form 8-K on August 30, 2022. The filing details the entry into a new material definitive credit agreement and the simultaneous termination of the company's existing credit facility dated June 3, 2019.
Key Financial Metrics and Debt Structure
The filing outlines a new Credit Agreement with the following terms:
- Revolving Facility: $75 million secured revolving credit facility maturing on August 30, 2027.
- Term Facility: $30 million term loan commitment available in up to six drawings until March 1, 2024. Repayment begins after March 1, 2024, in equal quarterly installments of approximately 3.57% of the funded principal, with the remainder due at maturity.
- Expansion Option: An uncommitted feature to increase total commitments by up to an additional $75 million in $5 million increments.
- Interest Rates: Based on Adjusted Term SOFR or Alternate Base Rate (ABR) plus a margin tied to the total leverage ratio (SOFR margin: 1.25%–1.75%; ABR margin: 0.25%–0.75%).
- Fees: Revolving facility commitment fee of 0.20%–0.25% on unused portions; Term facility ticking fee of 0.20%–0.25% on daily commitments.
- Collateral: Obligations are secured by first priority security interests in substantially all assets of AngioDynamics and its material domestic subsidiaries.
Material Changes Versus Prior Period
The primary material change is the refinancing of the company's debt structure. AngioDynamics utilized proceeds from the new Credit Agreement to repay all outstanding amounts under the Existing Credit Agreement, which was subsequently terminated without penalty. The new agreement extends the maturity date to 2027 and introduces a specific term loan tranche intended to finance manufacturing costs for Auryon laser capital equipment.
Financial Covenants and Risks
The new Credit Agreement imposes two key financial covenants effective for the fiscal quarter ended August 31, 2022:
- Fixed Charge Coverage Ratio: Must maintain a ratio of not less than 1.25 to 1.00.
- Total Leverage Ratio: Must maintain a ratio of not greater than 3.00 to 1.00. This threshold may increase to 3.50 to 1.00 during certain periods following material acquisitions.
The filing does not provide specific revenue, profit, cash flow, or liquidity figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Investor Verification Checklist
- Verify the company's current Total Leverage Ratio and Fixed Charge Coverage Ratio to ensure compliance with the new 3.00 and 1.25 thresholds, respectively.
- Review the actual utilization of the $30 million Term Facility for Auryon laser equipment financing.
- Monitor the interest rate environment (SOFR and ABR) to assess the impact on future interest expense given the variable rate structure.
- Check for any material acquisitions that might trigger the temporary increase in the leverage ratio covenant to 3.50 to 1.00.